Your browser doesn't support javascript.
loading
Designing and expression of novel recombinant fusion protein for efficient antigen screening of SARS-CoV-2.
Vidyasagar, G Vinaya Chandu; Reddy, P V Janardhan; Ghouse, M Md; Venkateswarulu, T C; Kishor, P B Kavi; Suravajhala, Prashanth; Polavarapu, Rathnagiri.
Affiliation
  • Vidyasagar GVC; Genomix CARL Pvt. Ltd, YSR Kadapa, Pulivendula, 516 390, Andhra Pradesh, India.
  • Reddy PVJ; Department of Biotechnology, Vignan's Foundation for Science, Technology & Research, Vadlamudi, Guntur, 522 213, India.
  • Ghouse MM; Genomix CARL Pvt. Ltd, YSR Kadapa, Pulivendula, 516 390, Andhra Pradesh, India.
  • Venkateswarulu TC; Genomix CARL Pvt. Ltd, YSR Kadapa, Pulivendula, 516 390, Andhra Pradesh, India.
  • Kishor PBK; Department of Biotechnology, Vignan's Foundation for Science, Technology & Research, Vadlamudi, Guntur, 522 213, India.
  • Suravajhala P; Genomix CARL Pvt. Ltd, YSR Kadapa, Pulivendula, 516 390, Andhra Pradesh, India.
  • Polavarapu R; Department of Genetics, Osmania University, Hyderabad, 500 007, India.
AMB Express ; 14(1): 80, 2024 Jul 11.
Article in En | MEDLINE | ID: mdl-38990364
ABSTRACT
Corona virus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), claimed millions globally. After the report of the first incidence of the virus, variants emerged with each posing a unique threat than its predecessors. Though many advanced diagnostic assays like real-time PCR are available for screening of SARS-CoV-2, their applications are being hindered because of accessibility and cost. With the advent of rapid assays for antigenic screening of SARS-CoV-2 made diagnostics far easy as the assays are rapid, cost-effective and can be used at point-of-care settings. In the present study, a fusion construct was made utilising highly immunogenic B cell epitopes from the three important structural proteins of SARS-CoV-2. The protein was expressed; purified capture mAbs generated and rapid antigen assay was developed. Eight hundred and forty nasopharyngeal swab samples were screened for the evaluation of the developed assay which showed 37.14% positivity, 96.51% and 100% sensitivity and specificity respectively. The assay developed was supposed to identify SARS-CoV-2 wild-type as well as variants of concern and variants of importance in real-time conditions.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: AMB Express Year: 2024 Document type: Article Affiliation country: India Country of publication: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: AMB Express Year: 2024 Document type: Article Affiliation country: India Country of publication: Alemania